Rejected at 11:06 a.m. Feb, 08, 2025 ] by thomas.holmes
Bulk Suggestion Bulk ID: joshuamb/01.28.25-05:18PM
Author: joshuamb
Related Note: 1509289237576
Rationale for change

See page 445 in FA2024

See this link at AMBOSS
https://next.amboss.com/us/article/4m03fg?q=vinblastine%20vs%20vincristine#Zd81f442fc4204146e3dc72044029e13d

I believe this may have been inspired by super classic regimens like RCHOP or ABVD but none of the sources support the link reinforced in this card specifically.
Source: AMBOSS - https://next.amboss.com/us/article/4m03fg?q=vinblastine%20vs%20vincristine#Zd81f442fc4204146e3dc72044029e13d

Rejection reason

see discussion for full explanation, but if you look up NHL and HL in Amboss, under treatment they both state that these regimens are the most common treatment for NHL and HL

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::10_Cell_Cycle_Dependent_Drug_Targets #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::04_Non_Hodgkin_Lymphoma_SOAP #AK_Step1_v12::#OME_banner #AK_Step1_v12::#Bootcamp::Genetics::04_Mitosis,_Meiosis,_and_the_Cell_Cycle::01_Mitosis #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::02_DNA_&_Cellular_Division::05_Mitotic_Inhibitors #AK_Step1_v12::#AMBOSS::z-0r-i #PANCE::HEME::neoplasms_premalignancies_malignancies #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#Low/HighYield::5-LowYield #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::15_Microtubule_inhibitors::*Vinca_Alkaloids